trialport thanked RARE Revolution Magazine for a piece on readifit and the thinking behind it.

trialport is a clinical trial navigation and decision-support platform. We help people find clinical trials, understand them in plain language, and decide with confidence whether a study fits their health and their life. People search for clinical trials every day. Far fewer understand what they find. A person can locate a study and still not know what participation involves, whether they are likely to be eligible, whether it fits their daily life, or whether they feel ready for the next step. The issue is not just access. It is comprehension at the moment of choice. trialport is an AI native clarity layer for clinical trials, built to improve decision quality before formal screening begins. For every study we provide: • A plain-language summary with medifit™ + readifit™ self-reflection tools • medifit: Is this trial right for my health? • readifit: Is this trial right for my life? • Neutral decision support grounded in behavioral science and shared decision making • Support for clinical trial readiness and better-prepared next steps trialport does not recruit participants. We support the patient recruitment and enrollment activities of sponsors, CROs, and clinical trial sites by improving understanding upstream: better-prepared referrals, stronger patient engagement, reduced screening friction, and clearer signal on fit and readiness. The trialport Live Network is our embedded distribution and engagement layer. It reaches people through trusted environments, from grassroots to global charity and patient advocacy groups, pathology labs, pharmacy networks, early access providers, patient research panels, point-of-care access, and trusted media partners. Our experienced team brings a proven track record across AI, engineering, product development, clinical operations, patient engagement, clinical trial site management, and Phase I to III studies, from both biopharma and commercial trial-unit perspectives. Understanding comes first. Decisions follow.